NCT05478499CompletedPhase 4
Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP)
Source: ClinicalTrials.gov · Last updated 28 Oct 2025
Brief summary (registry, in English)
The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 154 (actual)
- First submitted
- 27 Jul 2022
- Start date
- 6 Oct 2022
- Primary completion date
- 11 Jan 2024
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Psoriasis
- NCT number
- NCT05478499
- EudraCT number
- 2022-000797-26
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 154
- From 6 Oct 2022 to the primary completion date, 11 Jan 2024
- 29 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Target Disease Exceptions:
- Has nonplaque psoriasis (ie, guttate, inverse, pustular, erythrodermic or drug-induced psoriasis) at Screening or Day 1 Other protocol-defined inclusion/exclusion criteria apply
Who the study is looking for
- Men and women diagnosed with stable plaque psoriasis with scalp involvement for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the Investigator
- Deemed by the Investigator to be a candidate for phototherapy or systemic therapy
- Moderate-to-severe scalp psoriasis as defined by scalp-specific Physician's Global Assessment (ss-PGA) ≥ 3; ≥ 20% scalp surface area (SSA); Psoriasis Scalp Severity Index (PSSI) ≥ 12 at the Screening visit and Day 1
- ≥ 3% of Body Surface Area (BSA) involvement at the Screening visit and Day 1
- Evidence of plaque psoriasis in a non-scalp area
- Failed to respond to, or intolerant of ≥ 1 topical therapy for scalp psoriasis
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (29)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.